The appropriate management of patients discharged from the emergency department (ED) with increased high-sensitivity cardiac troponin T (hs-cTnT) but normal or borderline-high conventional cardiac troponin concentrations is unknown.
The management of patients who present to the emergency department (ED) 7 with acute chest pain is an important clinical challenge (1, 2 ) . Although some patients have typical symptoms or electrocardiogram (ECG) changes indicating acute myocardial infarction (AMI), the majority of patients will require a battery of tests to rule out AMI. The combination of various tests in ED patients, if poorly sensitive, will lead to the hazardous discharge of patients with an AMI and therefore a high risk of adverse events (3 ) . Poor specificity, however, will lead to the admission of a large number of low-risk patients, further increasing the use of resources and cost.
For the past 10 years, cardiac troponins have emerged as the key diagnostic biomarker for patients with acute chest pain suggestive of AMI (4, 5 ) . Therefore negative serial cardiac troponin measurements, in addition to clinical assessment, allow for the identification of a population at low risk for cardiac events (6, 7 ) .
Recently, high-sensitivity cardiac troponin assays (hs-cTn) have been developed, enabling the detection of concentrations that are 10 times lower than previously measurable. These assays have a significantly higher accuracy in the early diagnosis of AMI than conventional assays (8 -10 ) . However, concerns have been raised concerning the probable detection of increased hs-cTn concentrations in patients without AMI (11, 12 ) . The appropriate management of acute chest pain patients with increases in hs-cTn that are undetectable with conventional cardiac troponin assays is unknown. The possible spectrum of options ranges from admission to a cardiac intensive care unit, in the case of AMI, to outpatient management. The use of resources and costs varies dramatically between these options, with average costs exceeding $1000/day at many institutions (13 ) . The uncertainty regarding the appropriate management of these patients has contributed substantially to the reluctance to apply hs-cTn assays in clinical practice (14 ) .
We sought to determine the incidence of increased hs-cTnT concentrations above the 99th percentile in acute chest pain patients managed as outpatients and to examine their short-and long-term outcomes.
Methods
The design and first results of the Advantageous Predictors of Acute Coronary Syndromes Evaluation (APACE) study have been reported (10 ) . Briefly, APACE is an ongoing prospective, international, multicenter study coordinated by the University Hospital Basel that enrolls patients who present to the ED with chest pain of Ͻ12 h suggestive of AMI. Patients with terminal kidney failure requiring dialysis were not included in the study. In the present study, we analyzed a subgroup of patients from the APACE study that included those who were discharged from the ED after an AMI had been ruled out and were subsequently managed as outpatients. The attending ED physician ruled out AMI by use of serial measurements of cardiac troponin during careful monitoring (15 ) . The study was carried out according to the principles of the Declaration of Helsinki and has been approved by the local ethics committee.
CLINICAL ASSESSMENT AND INVESTIGATIONS
On admission to the hospital, all patients underwent a detailed clinical evaluation, 12-lead ECG, screening blood tests, and chest roentgenogram.
Cardiac troponins were measured at presentation and 6 -9 h after presentation or as long as clinically indicated, at the discretion of the attending physician. The following cardiac troponin assays were used for the clinical care of the patients at the participating hospitals: Abbott Axsym cTnI ADV, Beckmann Coulter Accu cTnI, and Roche cTnT 4th generation; all are validated current cardiac troponin assays with comparable performance in the diagnosis of AMI (16, 17 ) . Patient management, including treatment and possible discharge, was at the sole discretion of the ED doctor in charge and was based on the same information for all patients.
INVESTIGATIONAL CARDIAC TROPONIN ANALYSIS
Blood samples for determination of hs-cTnT (Roche Diagnostics) were collected at presentation to the ED and repeated unless the diagnosis of AMI was certain or the patient had to be transferred to the catheter laboratory or coronary care unit for management. After centrifugation, samples were frozen at Ϫ80°C until assayed in a blinded fashion on the Elecsys 2010 (Roche Diagnostics) in a dedicated core laboratory. The 99th-percentile cutoff point of the hs-cTnT assay is 14 ng/L, and the assay CV is Ͻ10% at 13 ng/L (10 ) . A change in hs-cTnT Ն20% within 3 h was considered to have clinical significance, assuming a near-linear relationship between time and the magnitude of change in cardiac troponin and the commonly used criterion of 30% within 6 h with a conventional cardiac troponin assay (9, (15) (16) (17) (18) .
REFERENCE STANDARD DIAGNOSIS
To determine the final diagnosis for each patient, 2 independent cardiologists blinded to hs-cTnT reviewed all medical records available at 60 days after presentation, including diagnostic procedures that were performed after discharge. Disagreements were resolved in conjunction with a third cardiologist (see Supplemental Data, which accompanies the online version of this article at http://www.clinchem.org /content/vol58/issue5).
FOLLOW-UP AND OUTCOME ASSESSMENT
The primary endpoint was all cause-mortality recorded during follow-up at 30, 90, and 360 days. For more details, see online Supplemental Data.
STATISTICAL ANALYSIS
The data are expressed as mean (SD) for variables with a gaussian distribution, median [interquartile range (IQR)] for variables with a nongaussian distribution, and n (%) for categorical variables; we made statistical data comparisons using Student's t-test, MannWhitney test, 2 test, or Fisher exact test, as appropriate. The mortality rate was reported graphically by use of the Kaplan-Meier method; the log-rank test was applied for the time to death. To assess the prognostic utility of hs-cTnT in our population, we compared patients discharged from the ED with or without increased hs-cTnT Ͼ99th percentile and data from patients with AMI managed as inpatients. The possible associated factors with 1-year mortality and AMI occurrence were investigated with univariable and multivariable logistic regression. We used STATA statistical software version 10.1 (StataCorp LP) for all analyses, P Ͻ 0.05 for significance.
Results
Of 1247 enrolled patients in the APACE database, 677 (54%) were discharged from the ED after thorough clinical assessment including serial measurements of cardiac markers and median 6 h (IQR 4 -8) of observation. Blinded baseline hs-cTnT concentrations were available in 643 patients (95%), who represent the final cohort (Table 1) .
CLINICAL MANAGEMENT IN THE ED
Serial clinical cardiac troponin measurements were obtained in 457 patients (71%). The median time interval between the first and second blood draws was 6 h. Median time from chest pain onset to presentation at the ED was 4 (2-5) h, and the median duration of observation in the ED was 3 (2-5) h in patients without serial cardiac troponin measurements.
ADJUDICATED REFERENCE STANDARD DIAGNOSIS
The reference standard diagnosis is represented in Fig. 1. Most patients who had an adjudicated reference standard diagnosis of unstable angina had a clinical diagnosis at discharge of "chest pain of unclear origin" and were scheduled for subsequent cardiac outpatient testing including exercise ECG, nuclear perfusion scanning, and coronary angiography.
BLINDED hs-cTnT
Median hs-cTnT concentration measured at presentation was 6 ng/L (IQR 3-11 ng/L), which is within the reference interval (Յ14 ng/L), in 529 (82%) patients and was increased (Ͼ14 ng/L) in 114 (18%) patients ( Fig. 1) . Most of these increases were mild, with hscTnT Ͻ30 ng/L in 95% and Ͻ50 ng/L in 98% of the entire cohort. In addition to the measurement at presentation, hs-cTnT was measured after 1 h in 83% of patients and at 2 and 3 h in 70% of patients. Among the 114 patients with increased hs-cTnT at baseline, only 21 patients (18%) had a rising/falling pattern of Ͼ20%, 18 patients (16%) had Ͼ30%, and 8 patients (7%) had Ͼ50%.
Patients with increased hs-cTnT were older and had more frequent cardiovascular risk factors and preexisting cardiovascular diseases (Table 1) . By multivariable regression analysis, age [odds ratio (OR) 1.09, 95% CI 1.06 -1.11, P Ͻ 0.001], reduced systolic blood pressure (OR 0.98, 95% CI 0.97-0.99, P ϭ 0.001), reduced glomerular filtration rate (OR 0.98, 95% CI 0.97-1.00, P ϭ 0.017), and the presence of ST-segment depression (OR 3.47, 95% CI 1.41-8.53, P ϭ 0.007) were independently associated with increased hs-cTnT concentration. Discharge medication was comparable to the medication taken before presentation (aspirin 54% vs 53% before and after discharge, respectively, ␤-adrenergic blocker 55% vs 50%, ACE inhibitors/angiotensin II receptor antagonist 47% vs 47%, statins 43% vs 44%). The adjudicated reference diagnosis in the majority of patients with increased hs-cTnT concentration was noncardiac chest pain and cardiac but noncoronary chest pain (Fig. 1) . Among the subgroup of 16 patients with an adjudicated reference standard diagnosis of unstable angina, coronary anatomy was known from previous coronary angiograms in 5 patients, and 8 patients were considered candidates for conservative or even palliative care due to extensive comorbidities or advanced age. Elective coronary angiography followed by angioplasty and stenting was performed during follow-up in 3 of 114 patients (3%) with increased hs-cTnT. In 4 patients (4%), elective coronary angiography revealed no significant coronary stenoses. Cardiac stress tests, including single photon emission computed tomography, were performed in 24 patients (21%).
FOLLOW-UP AND OUTCOME
Clinical follow-up was obtained in 99.4% of the cohort at 30 days (100% in patients with increased hs-cTnT concentrations), 96.9% at 90 days, and 82.4% at 360 days.
At 30-day follow-up, 1 study participant was deceased. From patient chart review, this participant was a 87-year-old woman presenting with unstable angina due to known coronary artery disease who had extensive comorbidities including recurrent strokes. Her hs-cTnT was 29 ng/L. She was asymptomatic after initial treatment and discharged from the ED with palliative care. A single patient (0.2%) had recurrent AMI within 30 days; baseline hs-cTnT was 11 ng/L, and the adjudicated reference standard diagnosis was unstable angina. Table 2 shows outcomes according to hs-cTnT concentrations. Allcause mortality and AMI rates at 30 days were 0.9% and 0.0%, respectively, in patients with increased hs-cTnT vs 0.0% and 0.2%, respectively, in patients with hs-cTnT within the reference interval (P ϭ 0.178 for mortality, P ϭ 0.641 for AMI).
All-cause mortality was 2.7% at 90 days and 5.2% at 360 days in patients with increased hs-cTnT concentrations vs 0.0% at 90 days and 0.2% at 360 days in patients with hs-cTnT within the reference interval (P ϭ 0.006, P ϭ 0.001 respectively) ( Table 2 , Fig. 2 ). Two patients with increased hs-cTnT at presentation died from cardiac cause (including the patient considered as palliative who died within 30 days), 1 died from sepsis, and 1 died from respiratory failure; the cause of death remains unknown in the remaining patients. One patient whose hs-cTnT was in the reference interval died from cancer. The rate of AMI was increased in patients with increased hs-cTnT concentrations vs patients whose hs-cTnT was within the reference interval (P ϭ 0.081 at 90 days, P ϭ 0.001 at 360 days) ( Table 2) . Table 3 shows the factors associated with 360-day mortality/AMI.
For a more in-depth picture of the prognostic significance of mild increases in hs-cTnT, we provided bin-depth characteristics (Table 4) and mortality data of patients with proven AMI treated in hospital (Fig. 2) . It is noteworthy that these patients with AMI had in- 
Discussion
This multicenter study evaluated the safety of outpatient management in patients with acute chest pain and increased circulating hs-cTnT but normal or borderline-high conventional cardiac troponin and for whom discharge was deemed appropriate on the basis of clinical assessment after a median 6 h of observation and serial cardiac troponin measurements. We report 4 major findings. First, 18% of discharged patients had increased hs-cTnT above the 99th percentile. Second, when hs-cTnT was found to be increased initially, it was only mildly increased and remained stable during the observation period in most patients. Third, hscTnT concentrations were strongly prognostic for 90-day and 360-day mortality and AMI. Fourth, outpatient management of the patients with mild and chronic increases in hs-cTnT was associated with a mortality rate of only 0.9% at 30 days and a 0% rate of AMI. Our findings have relevant clinical implications and concur with previous studies on the management of patients with acute chest pain. In the majority of patients discharged after observation and serial cardiac troponin measurements, the adjudicated diagnosis was cardiac, noncardiac, or unknown cause of chest pain. Due to the observational design of this study and the absence of systematic detailed investigations, we cannot provide detailed explanations for the specific causes of the mostly chronic increases in hs-cTnT in all of these patients. Previous studies applying computed tomography/angiography have shown that even in the absence of acute ischemic heart disease, hs-cTnT concentrations correlate with the presence and severity of structural cardiac disease including stable coronary artery disease (19, 20 ) . It is important to note that the cause of acute chest pain may be different from the cause of hs-cTnT increase. Although the prevalence of a history of coronary artery disease was only 30%, the incidence of increased hs-cTnT concentrations in our cohort was higher than the rate observed in patients with stable coronary artery disease according to the same hs-cTnT assay (11, 12 ) . The independent factors associated with increased hs-cTnT in our cohort were ECG changes, increased age, reduced systolic blood pressure, and renal failure, which are all known to be associated with advanced cardiac disease and altered prognosis (12, 21 ) . This suggests that previously unknown cardiac disease (e.g., hypertensive heart disease in a patient with hypertension) could be the cause of the hs-cTnT increases in many patients, a finding consistent with a recent study (19 ) . Our findings may help to reassure ED physicians and consulting cardiologists regarding conservative management decisions in those patients with acute chest pain, intermediate or low likelihood of acute coronary syndrome, and mildly increased but stable hs-cTnT concentrations (14 ) . As a consequence, the majority of these patients have a reference standard adjudicated diagnosis of cardiac but noncoronary or noncardiac cause of chest pain. Thirty-day mortality and AMI rates were rather low (0.9% and 0%, respectively), possibly documenting the feasibility and safety of outpatient management of these patients. In addition, the observed single death within 30 days could be described as "expected." This population corresponds to patients at low or intermediate likelihood of acute coronary syndrome (22 ) , with mild increases in hs-cTnT (Ͻ50 ng/ L), which remains stable within 3 h.
One-year mortality in these patients with acute chest pain and mildly increased hs-cTnT was 2 times higher than in the average healthy control of the same age and ethnic background (23 ) , and was also higher than observed in patients with stable coronary artery disease (24 ) . Long-term prognostic significance of cardiac troponin has been reported (7, 11, 12, 25 ) . Our study also highlights the ability of cardiac troponin to predict AMI in patients with acute chest pain, whereas previous studies showed that cardiac troponin was predictive of death but not AMI in patients with established acute coronary syndromes or stable coronary artery disease (11, 12 ) .
The strong association between increased hs-cTnT concentrations and the long-term risk of death or AMI suggests that mild hs-cTnT increases should be considered an opportunity to carefully reassess the diagnosis. The majority of these patients have a noncoronary cause of chest pain, but some patients with missed diagnosis of ACS will be identified. Increases in hs-cTnT, although mild and chronic, are to be considered a strong indication for further detailed cardiac investigations (i.e., echocardiography, stress testing, coronary angiography) and treatment. However, there are no data suggesting that any of these investigations require immediate hospitalization or that immediate hospitalization would have deterred any of the clinical events observed It is important to stress that our data in no way suggest that patients who would otherwise be admitted, such as patients at high likelihood of acute coronary syndrome, should be discharged. Our observation was derived from patients in whom discharge was deemed appropriate on the basis of clinical assessment, observation, and serial conventional cardiac troponin measurements. This study has several limitations. First, we observed a very low mortality rate, precluding any subgroup analysis. Second, the limited numbers of patients with increased hs-cTnT concentrations led to large confidence intervals. Our study is the first one to suggest that outpatient management might be safe in these patients; this has to be confirmed in additional studies. Third, the adjudicating cardiologists were able to reach the final diagnosis of AMI or non-AMI in all patients, but cardiac investigations were not considered conclusive enough to definitely diagnose or rule out unstable angina in 12% of patients. Fourth, the number of coronary angiograms and other cardiac imaging procedures performed in those patients managed as outpatients was low. Therefore, our dataset is not well suited to investigate detailed mechanisms behind the mild and mostly chronic increases in hs-cTnT we observed. Fifth, the median time from onset of chest pain to presentation was 4 h in this cohort. Although we observed no difference in outcomes between early vs late presenters, our findings might not apply to patients presenting very early after chest pain onset. Sixth, because we evaluated the hs-cTnT assay, our findings regarding risk stratification can be generalized to only other hs-cTn assays, as defined by Apple (26 ) , but not to assays with lower sensitivity and precision.
In conclusion, hs-cTnT is a strong prognosticator regarding long-term mortality and AMI in low-risk patients with noncoronary causes of chest pain. HS-cTnT seems to identify patients who may benefit from further cardiac investigations and therapy. Low shortterm mortality suggests that further cardiac investigations and therapy in an outpatient setting may be the appropriate management in most of these patients.
